HANX, the UK-based sexual wellness and intimate care brand, has announced a significant expansion of its digital pharmacy services with the introduction of GLP-1 medications, marking its evolution into the broader femtech category. The new weight management offering is designed to support women struggling with conditions like Polycystic Ovary Syndrome (PCOS), endometriosis, and menopause.
The GLP-1 medications, Mounjaro (tirzepatide) and Wegovy (semaglutide), form the cornerstone of this initiative. These injectable medications will be prescribed to eligible patients as part of a comprehensive weight management program that also includes nutrition and exercise guidance. The program aims to provide women with sustainable support on their weight loss journey, addressing a critical aspect of women’s health that has often been overlooked.
“In the 10+ years I worked in NHS clinics, I heard from many patients about their struggles to manage weight, especially during menopause or when navigating conditions such as PCOS or endometriosis. In these cases, lifestyle changes alone aren’t always enough to support sustainable, successful weight loss,” said Dr. Sarah Welsh, Co-Founder and Chief Product Officer of HANX. “Maintaining a healthy weight is essential for our broader health and can reduce the risk of health problems such as heart disease and cancer. By offering our patients the option of safe, effective medication with educational resources, we’re aiming to truly support women on their weight management journey.”
GLP-1 medications work by decreasing cravings, reducing blood sugar, and delaying gastric emptying, helping patients feel fuller for longer. When combined with the lifestyle changes outlined in HANX’s new weight management program, patients can expect to lose up to 22.5% of their body weight within a year, according to studies published in The New England Journal of Medicine.
The process for joining the HANX Weight Management Programme begins with a digital health consultation on the HANX platform. Each consultation is reviewed by a prescribing pharmacist, and if deemed safe and suitable, customers can begin the program. The program includes GLP-1 medication, educational content, and monthly check-ins.
HANX’s move into weight management is part of its broader vision to support women at every stage of life. “We’ve spent the last seven years building trust and authority in the women’s health space, and have always been at the forefront with trusted and backable solutions, from prescription birth control to medical device-grade products,” said Farah Kabir, Co-Founder and CEO of HANX. “I am delighted to be adding the latest groundbreaking, science-backed GLP-1 medication to our pharmacy repository. From fertility to libido to our menstrual cycles, weight has an impact on many core elements of women’s health and it’s time we connect the dots. We’re proud to be the first women’s health brand to launch GLP-1 medications and believe strategically, it’s the natural next step for HANX. We can’t wait to offer our community these revolutionary tools to help them advocate for their health for the long term.”
The Weight Management Programme is the latest addition to HANX’s established digital pharmacy, which also offers same-day dispatch of intimate care treatments, hormonal contraception on subscription, and emergency contraceptive pills.
